BDX SEC Filings

Becton, Dickinson and Company (BD) announced the resumption of shipments for its ChloraPrep™ product in the U.S. This follows a voluntary ship hold initiated on May 6, 2026, for ChloraPrep™ and PurPrep™ while the company conducted additional final release testing. The company has stated that all subsequent testing has been acceptable and, importantly, there have been no reported patient safety signals associated with these products. This action is a direct response to a Warning Letter received from the FDA concerning the El Paso manufacturing facility. While the immediate concern regarding product shipment has been addressed with acceptable testing results, investors should note that the underlying issues related to the El Paso Warning Letter remain. BD directs stakeholders to their Form 10-Q for the quarter ended March 31, 2026, for a detailed description of the Warning Letter and associated risks, as well as their latest 10-K and other SEC filings for forward-looking statement disclaimers.

Becton, Dickinson and Company (BDX) has announced through its indirect wholly-owned subsidiary, Becton Dickinson Euro Finance S.à r.l., the issuance of €600 million in aggregate principal amount of 3.855% Notes due 2033. These notes are senior unsecured and fully guaranteed by BDX, providing investors with a direct credit commitment from the parent company. The primary use of proceeds from this offering is to refinance existing debt, specifically Becton Finance's 1.208% Notes due June 4, 2026. This strategic move aims to extend the company's debt maturity profile and potentially reduce interest expenses. The offering introduces several provisions for noteholders, including options for early redemption by Becton Finance under specific conditions related to interest rates and the ability to redeem at par after February 20, 2033. Importantly, the notes include provisions for additional payments in case of withholding taxes imposed by Luxembourg or the United States, and a repurchase obligation at 101% of principal if a Change of Control Triggering Event occurs. The indenture also outlines events of default and restrictive covenants typical for such debt issuances.

Becton, Dickinson and Company (BDX) has announced a significant debt offering through its indirect wholly-owned subsidiary, Becton Dickinson Euro Finance S.à r.l. The company entered into an underwriting agreement to issue €600 million in aggregate principal amount of 3.855% Notes due 2033. These Euro Notes will be fully and unconditionally guaranteed on a senior unsecured basis by Becton Dickinson & Co. This offering is primarily intended to refinance existing debt, specifically the entire outstanding principal amount of the 1.208% Euro Notes due June 4, 2026. The net proceeds, combined with cash on hand, will be used to repay this maturing debt, along with accrued interest and associated fees. This move indicates proactive financial management by BDX to address upcoming maturities and potentially optimize its debt structure.

Becton Dickinson & Co. (BDX) reported a net loss of $311 million for the third quarter of fiscal year 2026, a significant shift from the net income of $308 million in the prior-year period. This was largely driven by a $274 million loss from discontinued operations, primarily due to the February 9, 2026, spin-off of its former Biosciences and Diagnostic Solutions business as part of a Reverse Morris Trust transaction with Waters Corporation. Revenues for the quarter increased by 5.2% to $4.714 billion, demonstrating underlying business growth. However, the company faced increased operating costs, including integration, restructuring, and transaction expenses, which impacted profitability. The company also announced a substantial $2 billion share repurchase program funded by proceeds from the spin-off, alongside continued dividend payments to shareholders. Management is focused on its "Excellence Unleashed" strategy to drive future growth and operational efficiency.

Becton Dickinson & Co. (BDX) has officially appointed Vitor Roque as its Executive Vice President and Chief Financial Officer (CFO), effective May 7, 2026. This formalizes his role following his interim appointment as CFO in December 2025. The company has also outlined Mr. Roque's compensation package, which includes a base salary of $770,000, an annual target bonus of 95% of his base salary, and an annual target equity compensation value of $3,000,000. These figures are pro-rated for the current fiscal year. Additionally, Mr. Roque will receive a one-time cash payment of $250,000 and a $250,000 time-vested equity award in recognition of his service as interim CFO. This appointment and compensation structure provide clarity on the leadership of BDX's financial operations moving forward. Investors can note that Mr. Roque's terms are aligned with those of other senior executives, including a two-year severance agreement following a change of control. There are no disclosed related-party transactions or unusual arrangements regarding his appointment. The company also furnished a press release announcing this development.

Becton, Dickinson and Company (BDX) filed an 8-K on May 7, 2026, to report its financial results for the second fiscal quarter ending March 31, 2026. The core of the filing is a press release (Exhibit 99.1) that provides the company's operational and financial performance for the period. Investors should note that the press release includes non-GAAP financial measures alongside GAAP figures, and details on these adjustments are available within the furnished exhibit.

Becton, Dickinson and Company (BDX) filed an 8-K on April 29, 2026, to report amendments to its By-laws, approved by the Board of Directors on April 28, 2026. These changes are primarily technical and administrative in nature, aiming to clarify and update existing provisions rather than signaling a fundamental shift in the company's operations or financial strategy. Investors should note that the core update involves the advance notice provision concerning contested director elections. While the specific details of the updated time period are not elaborated in this filing, the amendment aims to streamline the process for determining contested election statuses. Other revisions are described as technical, conforming, and clarifying, suggesting minor housekeeping adjustments to the Company's governing documents. No immediate financial impacts or strategic changes are indicated by this filing.

Becton, Dickinson and Company (BDX) announced on April 9, 2026, that Richard E. Byrd, Executive Vice President and President of its Interventional segment, has informed the company of his intention to retire. Mr. Byrd will continue in his role until June, and the company expects to name a successor before his departure. This leadership transition in a key segment is the primary focus of this filing. While no immediate financial impact or strategic shift is detailed, investors should monitor the appointment of Mr. Byrd's successor. The company's ability to ensure a smooth transition and appoint a leader capable of driving the Interventional segment forward will be crucial for continued performance and investor confidence. This 8-K filing serves to formally disclose this executive departure and is accompanied by a press release furnished under Regulation FD.

Becton, Dickinson and Company (BD) filed an 8-K on April 2, 2026, to provide investors with updated financial information following the spin-off and combination of its Biosciences and Diagnostic Solutions business with Waters Corporation, which was completed on February 9, 2026. The company has furnished recast historical financial information to present its standalone operating results from continuing operations, effectively treating the divested business segment as discontinued operations. This filing is crucial for investors to understand BD's performance and financial condition on a go-forward basis, separate from the divested segment. The provided recast financial information includes non-GAAP measures, and investors are advised to review the accompanying schedules within Exhibit 99.1 for detailed explanations of these adjustments and their impact on the reported figures. This information is furnished and not deemed 'filed' for regulatory purposes.

Becton, Dickinson and Company (BDX) announced the early tender results and pricing for its previously announced cash tender offers for various series of its senior notes and debentures. The aggregate purchase price cap for these offers was set at $2,000,000,000. The company also exercised its right to increase the offer sub-cap for its 4.685% Senior Notes due 2044 and the overall aggregate offer cap. The early tender results indicate strong participation from noteholders, with several series exceeding their individual offer sub-caps and the aggregate offer cap. Consequently, the company will accept the 3.794% Senior Notes due 2050 on a prorated basis due to oversubscription.

Becton, Dickinson and Company (BDX) has announced the commencement of a significant tender offer program, seeking to repurchase up to $1.6 billion in aggregate principal amount of its outstanding senior notes and debentures. This action indicates a strategic move by the company to manage its debt obligations and potentially optimize its capital structure. Investors should note the broad range of maturities and coupon rates for the notes being tendered, suggesting a comprehensive approach to debt refinancing or deleveraging. The company's willingness to offer cash for these debt instruments, up to a substantial aggregate amount, may signal confidence in its current liquidity position and future cash flow generation. This tender offer is a key event for bondholders and could influence the company's future financing costs and overall financial flexibility.

Becton, Dickinson and Company (BD) has filed an 8-K report on February 9, 2026, to announce its financial results for the first fiscal quarter ending December 31, 2025. The filing primarily serves to furnish a press release, included as Exhibit 99.1, which details these quarterly results. Investors should note that this press release contains non-GAAP financial measures alongside GAAP measures. A reconciliation of these non-GAAP measures and further details on the adjustments made are available within the furnished press release itself.

Becton, Dickinson and Company (BDX) reported a modest increase in revenues for the fiscal first quarter ending December 31, 2025, with total revenues reaching $5.252 billion, up 1.6% from the prior year. This growth was primarily driven by favorable foreign currency impacts and moderate volume increases, despite some pricing headwinds. Net income rose to $382 million, resulting in diluted earnings per share of $1.34, a significant increase from $1.04 in the prior year, reflecting improved operational performance and the favorable impact of foreign currency. The company also announced the completion of a major transaction: the spin-off of its Biosciences and Diagnostic Solutions business, combined with Waters Corporation, which resulted in a significant cash distribution of $4 billion to BD. This strategic move is expected to reshape the company's future focus and financial structure. Operationally, the company saw varied performance across its segments. While Connected Care and Interventional segments showed strong revenue growth, driven by specific product lines like Advanced Patient Monitoring and Peripheral Intervention respectively, the Medical Essentials segment experienced slight declines. The Life Sciences segment, which is being divested, saw a notable decrease in revenues. Looking ahead, BD is prioritizing innovation, commercial excellence, and operational efficiency under its 'Excellence Unleashed' strategy. The significant cash influx from the Waters transaction provides ample opportunity for strategic deployment, including accelerated share repurchases and debt reduction, aiming to enhance shareholder value.

Becton Dickinson & Co. (BDX) has filed an 8-K report announcing the completion of significant "Transactions" with Waters Corporation and Augusta SpinCo Corporation. This filing details the entry into material definitive agreements, including a Tax Matters Agreement, an Employee Matters Agreement, an Intellectual Property Matters Agreement, and a Transition Services Agreement. These agreements govern the post-transaction relationship and operational aspects between BDX, Waters, and SpinCo. Additionally, the report confirms a cash distribution of $4 billion received from SpinCo, which BDX plans to utilize for $2 billion in share repurchases via an accelerated share repurchase program and $2 billion for debt repayment, aiming to enhance shareholder value and strengthen its balance sheet. The report also notes the resignation of a director who has joined the Waters board, a common occurrence in such spin-off or merger scenarios.

Becton Dickinson and Company (BDX) has announced a significant organizational restructuring, effective October 1, 2025, consolidating its operations into five distinct worldwide business segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences. This move aims to better align strategic business units that develop, manufacture, and market unique products and services. While the core product lines remain unchanged, this realignment is designed to enhance operational focus and potentially improve reporting clarity for investors moving forward. Of particular note for investors is the planned combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation, which is expected to result in the elimination of the Life Sciences segment from future reporting. This divestiture/combination will leave BD with four primary reportable segments. The company has furnished recast historical segment revenues for fiscal year 2025 and prior periods, presented under the new segment structure, to aid investors in understanding the historical performance in light of these changes. Investors should pay close attention to the details of the Life Sciences divestiture and the performance of the remaining four segments.

Becton, Dickinson and Company (BDX) filed an 8-K report detailing the issuance of Series D Junior Participating Redeemable Preferred Stock to certain employee benefit trusts. This issuance, occurring on February 2, 2026, was conducted in reliance on the Section 4(a)(2) exemption from registration requirements. The primary purpose of this transaction is to ensure these trusts do not receive shares of Augusta SpinCo Corporation common stock in the upcoming distribution, which is a component of the previously announced Reverse Morris Trust transaction with Waters Corporation. The Series D Preferred Stock is redeemable by the Company, at its option, for shares of BDX common stock. Importantly, if the distribution of SpinCo common stock proceeds as planned, the Series D Preferred Stock will automatically be redeemed for BDX common stock. This action is a strategic maneuver related to the RMT transaction, aiming to manage the distribution of assets and to comply with the terms of the pending combination with Waters Corporation. Investors should note this is an internal restructuring measure rather than a new equity offering to the public.

Becton, Dickinson and Company (BDX) has filed an 8-K report detailing key governance and compensation-related decisions made during its 2026 Annual Meeting of Shareholders. The most significant development is the adoption of the BD Executive Severance Plan, effective January 27, 2026. This plan establishes severance benefits for designated management employees, including executive officers, in the event of termination without "Cause." The severance package varies by executive level, with the CEO receiving 1.5 times base salary and target bonus, while other senior leaders receive 1.0 times these amounts. Benefits also include pro-rated bonuses, COBRA premium contributions, and outplacement services. Additionally, shareholders approved an amendment to the 2004 Employee and Director Equity-Based Compensation Plan, increasing the available shares for awards by approximately 3.9 million. This move is intended to support ongoing equity incentives for employees and directors. The report also confirms the election of all director nominees, the ratification of Ernst & Young as the independent auditor for fiscal year 2026, and advisory approval of executive compensation. These actions signal the company's focus on executive retention, long-term incentive alignment, and robust corporate governance.

Becton, Dickinson and Company (BDX) has filed an 8-K report detailing a temporary suspension of trading for participants in its 401(k) Plan. This "blackout period" is necessary to facilitate the integration of Waters Corporation (Waters) common stock interests into the plan, following a pending transaction between the two companies. The blackout will prevent participants from making any transactions involving their holdings in the BD Common Stock Fund, including exchanges, loans, withdrawals, or distributions, for a specified period around the transaction's closing. Investors should note that this filing primarily concerns the operational mechanics of employee benefit plans and does not appear to disclose new financial performance data or significant strategic shifts beyond the integration of Waters' stock. The primary impact is on BDX employees' ability to manage their retirement savings invested in company stock during the transition. Further details on the exact timing of the blackout will be made available through Fidelity, the plan administrator.

Becton Dickinson & Co. (BDX) has filed an 8-K/A amendment to its previous filing, primarily detailing changes related to its Board of Directors. Effective December 1, 2025, two new directors, Mr. Huffines and Ms. Wright, have been appointed to the Board. This appointment is accompanied by a compensation package for these new directors, consisting of restricted stock units (RSUs) valued at $33,575 each. These RSUs are prorated from their appointment date through the company's 2026 Annual Meeting of Shareholders, aligning their interests with long-term shareholder value.

Becton, Dickinson and Company (BDX) reported revenues of $21.84 billion for the fiscal year ending September 30, 2025, an increase of 8.2% year-over-year. This growth was primarily driven by the acquisition of Edwards Lifesciences' Critical Care product group, now known as BD Advanced Patient Monitoring, which contributed 4.8% to the revenue increase. The company continues to navigate a dynamic market, focusing on its strategic objectives of growth, simplification, and empowerment. BD also announced its definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation in a Reverse Morris Trust transaction, expected to close by the end of the first quarter of calendar year 2026, which will result in BD shareholders owning approximately 39.2% of the combined entity. Key operational highlights include continued growth across its Medical and Interventional segments, although the Life Sciences segment experienced a slight revenue decline. The company faces ongoing challenges related to supply chain disruptions, inflation, and regulatory complexities, particularly concerning the FDA's consent decree for its Alaris infusion pump business and a recent warning letter for its dispensing quality management system. BD is actively managing these challenges and investing in innovation and operational efficiency to drive future growth and shareholder value.

Becton, Dickinson and Company (BDX) announced a board refreshment through the election of two new independent directors, Robert L. Huffines and Jacqueline Wright, effective December 1, 2025. This expansion will increase the Board size from twelve to fourteen members. Ms. Wright will join the Audit Committee and the Compensation and Human Capital Committee, while Mr. Huffines will serve on the Audit Committee and the Corporate Governance and Nominating Committee. Both directors have been determined to meet the independence requirements of the New York Stock Exchange and BD's own governance principles. This move indicates a strategic strengthening of the Board's oversight capabilities and potentially a broadening of expertise. Investors should note that the specific details of the restricted stock units to be granted to the new directors will be supplemented in a future filing, which will provide further insight into their compensation and alignment with shareholder interests. The appointment of independent directors with relevant committee assignments is generally viewed positively by the market as it can lead to improved governance and strategic decision-making.

Becton, Dickinson and Company (BD) filed an 8-K on November 6, 2025, to announce its financial results for the fourth fiscal quarter ending September 30, 2025. The filing primarily serves as a notification that the company's press release detailing these results is available and furnished as an exhibit. Investors should refer to the press release (Exhibit 99.1) for specific financial performance details, including both GAAP and non-GAAP measures. The company emphasizes that adjustments for non-GAAP measures are further detailed within the press release itself, making it the essential document for understanding the quarter's financial condition and operational outcomes.

Becton, Dickinson and Company (BDX) has filed an 8-K report on October 15, 2025, primarily to announce preliminary unaudited revenue figures for its fourth quarter and full fiscal year ended September 30, 2025. While specific revenue numbers are not detailed in the 8-K text itself, investors are directed to Exhibit 99.1, a press release, for these details and a discussion of non-GAAP financial measures. This filing also discloses a significant leadership change: Executive Vice President and Chief Financial Officer, Christopher J. DelOrefice, will resign effective December 5, 2025, to pursue a new opportunity. His departure is stated to be amicable and not due to any disagreements regarding financial matters. Vitor Roque, currently Senior Vice President of Finance, Business Units and Corporate Financial Planning & Analysis, has been appointed interim Chief Financial Officer, effective upon Mr. DelOrefice's departure. Mr. Roque brings extensive experience within BDX, having held various senior finance roles, including CFO of the BD Medical Segment. The company is actively searching for a permanent CFO. Investors should review the furnished press release for detailed preliminary financial results and consider the implications of the CFO transition on future financial reporting and strategy.

Becton, Dickinson and Company (BDX) has entered into a third amended and restated credit agreement, enhancing its financial flexibility. This new agreement, effective September 16, 2025, provides the company with a senior unsecured revolving credit facility totaling $2.75 billion, with an option to increase it to $3.25 billion. The facility matures in September 2030 and includes subfacilities for letters of credit and swingline loans, with potential extensions available. This refinancing effort signals a proactive approach to managing its capital structure. The increased borrowing capacity can support general corporate purposes, strategic initiatives, and potential future acquisitions. The facility's terms include customary covenants, with a maximum Leverage Ratio of 4.25:1.00, stepping up to 4.75:1.00 following a material acquisition, providing flexibility while maintaining financial discipline.

Becton, Dickinson and Company (BDX) reported solid revenue growth for the third quarter of fiscal year 2025, with total revenues reaching $5.509 billion, a 10.4% increase year-over-year. This growth was significantly bolstered by the acquisition of Advanced Patient Monitoring and organic growth across its Medical and Interventional segments, which offset a slight decline in Life Sciences revenue. Diluted earnings per share also saw an increase to $2.00 from $1.68 in the prior-year period, demonstrating improved profitability. The company continues to execute its BD 2025 strategy, focusing on growth, simplification, and empowerment, and is strategically managing its capital through dividends and share repurchases. A significant strategic development is the definitive agreement to combine BD's Biosciences and Diagnostic Solutions business with Waters Corporation, structured as a Reverse Morris Trust. This transaction is expected to create a focused life science and diagnostics leader, with BD receiving a substantial cash distribution. While the transaction is projected to be tax-free for BD and its shareholders, its completion is subject to regulatory and shareholder approvals and is anticipated around the end of the first quarter of calendar year 2026. Management remains focused on navigating global economic factors and supply chain dynamics while pursuing innovation and operational efficiency.

Becton, Dickinson and Company (BDX) filed an 8-K on August 6, 2025, to report on its third fiscal quarter ended June 30, 2025. The primary purpose of this filing is to furnish a press release announcing the company's financial results for the quarter. Investors should note that the press release includes non-GAAP financial measures, and details regarding these adjustments are available within the provided press release document. While the 8-K itself does not contain detailed financial figures, it serves as the official notification that BDX has disseminated its quarterly earnings. Investors and analysts are directed to review the furnished press release (Exhibit 99.1) for comprehensive insights into the company's performance, including revenue, earnings per share, and any forward-looking guidance, as well as the specific methodologies for their non-GAAP reporting.

Becton, Dickinson and Company (BDX) has entered into definitive agreements to combine its Biosciences and Diagnostic Solutions business with Waters Corporation through a Reverse Morris Trust transaction. This strategic move involves separating the target business into a new entity, SpinCo, which will then merge with a subsidiary of Waters. As a result of this transaction, BDX will receive approximately $4 billion in cash, and its shareholders will own a 39.2% stake in the combined Waters entity. This transaction is expected to reshape BDX's business portfolio and provide significant capital for future endeavors. The deal has received unanimous approval from the Boards of Directors of both BDX and Waters. The transaction is structured through a separation of BDX's relevant business, a cash distribution to BDX, a spin-off of the new entity to BDX shareholders, and a subsequent merger with a Waters subsidiary. The consummation of this transaction is subject to various closing conditions, including regulatory approvals and the satisfaction of financing conditions.

Becton, Dickinson and Company (BD) has announced a significant strategic transaction where its Biosciences and Diagnostic Solutions business will be combined with Waters Corporation through a Reverse Morris Trust transaction. This move aims to create a new, independent public company poised for growth in the life sciences sector. While specific financial terms are not detailed in this 8-K filing, the company has published a joint press release, investor presentation, and an overview of the new BD business. Investors should note that this transaction is subject to customary closing conditions, including regulatory approvals and shareholder consent. BD and Waters will host a joint conference call to discuss the transaction, and further detailed information will be provided in subsequent SEC filings, including registration statements and proxy materials.

Becton, Dickinson and Company (BDX) has filed an 8-K report disclosing the pendency and proposed settlement of a consolidated stockholder derivative action. The lawsuit, captioned 'In re Becton, Dickinson and Company Stockholder Derivative Litigation' and 'Lotz v. Burzik, et al.', concerns alleged actions related to the company. Investors should review the 'Notice of Pendency and Proposed Settlement of Stockholder Action' (Exhibit 99.1) for detailed terms of the settlement and information regarding a related hearing. While this filing does not contain new financial results or operational updates, it addresses a material legal matter. The proposed settlement aims to resolve the derivative litigation, which could otherwise involve significant legal costs and potential judgments for the company. Investors are encouraged to understand the terms and implications of this settlement as it may impact future corporate governance practices or potential liabilities, though the filing itself states this information is not deemed 'filed' for Section 18 purposes.

Becton, Dickinson and Company (BDX) has filed an 8-K report to announce an amendment to its By-laws, effective April 29, 2025. The primary focus of these amendments is to update procedural and disclosure requirements concerning advance notice for shareholder nominations and other business at annual meetings. These revisions are particularly noteworthy for aligning with Rule 14a-19 of the Securities Exchange Act of 1934, which governs proxy solicitations and related disclosures. While these changes do not directly impact the company's financial performance or strategic operations in the immediate term, they are crucial for corporate governance and shareholder engagement. Investors should view these amendments as a proactive step by the Board of Directors to ensure compliance with evolving regulatory requirements and to maintain transparent processes for shareholder participation in annual meetings. The amendments also include updates to defined terms, order of business, and officer appointment provisions, suggesting a broader effort to modernize and clarify the Company's governing documents.

Becton, Dickinson and Company (BD) has filed a Form 8-K to report on its financial results for the second fiscal quarter ending March 31, 2025. The filing primarily furnishes a press release (Exhibit 99.1) that details these operational and financial outcomes. Investors should note that the press release includes non-GAAP financial measures, with further details and reconciliations provided within the document itself. This report is crucial for understanding BD's recent performance and forward-looking financial health, as detailed in the accompanying press release. While the 8-K itself is a notification filing, the core financial data and performance commentary reside within the furnished press release. Investors are advised to carefully review Exhibit 99.1 to grasp the company's revenue, profitability, segment performance, and any other key financial metrics and management commentary that may influence investment decisions. The use of non-GAAP measures underscores the importance of understanding the adjustments made by the company to present its financial results.

Becton Dickinson & Co. (BDX) reported revenues of $5.272 billion for the third quarter of fiscal year 2025, a 4.5% increase year-over-year. This growth was primarily driven by the acquisition of Advanced Patient Monitoring and solid performance in the Medical and Pharmaceutical Systems segments, though partially offset by challenges in the Life Sciences and Interventional segments. Net income for the quarter was $308 million, down from $537 million in the prior year period, resulting in diluted EPS of $1.07 compared to $1.85. The company announced its intention to separate its Biosciences and Diagnostic Solutions businesses, a move expected to be completed in fiscal year 2026, which aims to unlock shareholder value. Despite revenue growth, the decrease in net income was influenced by factors including purchase accounting adjustments, increased restructuring costs, and higher interest expenses related to recent acquisitions. BDX's balance sheet shows $8.67 billion in current assets and $7.69 billion in current liabilities as of March 31, 2025. The company generated $857 million in net cash from operating activities for the first six months of fiscal year 2025, a decrease from $1.369 billion in the prior year, attributed to changes in working capital, including higher inventory levels and lower accounts payable and accrued expenses. Significant financing activities included $876 million in debt payments and $750 million in share repurchases. The company continues to return capital to shareholders through dividends, with $600 million paid in the first six months of fiscal year 2025.

Becton, Dickinson and Company (BDX) announced a change to its Board of Directors, appointing Gregory J. Hayes as a new director effective March 26, 2025. This appointment also led to an expansion of the Board from eleven to twelve members. Mr. Hayes, deemed independent under NYSE and BD's governance rules, will bring his expertise to both the Audit Committee and the Compensation and Human Capital Committee. This move signifies a strengthening of the Board's oversight and strategic guidance capabilities. In conjunction with his appointment, Mr. Hayes will receive restricted stock units valued at $180,836. This compensation is structured as a prorated grant, reflecting his service from the election date until the 2026 Annual Meeting of Shareholders. Investors can anticipate further details on director compensation within BD's 2025 Annual Meeting proxy statement. The addition of Mr. Hayes is likely aimed at leveraging his experience to support BD's ongoing business objectives and corporate governance practices.

Becton Dickinson & Co. (BDX) reported a 9.8% increase in revenue for the first quarter of fiscal year 2025, reaching $5.168 billion, driven by a 5.7% boost from the recent acquisition of Advanced Patient Monitoring and organic growth across its segments. Net income grew to $303 million ($1.04 EPS) from $281 million ($0.97 EPS) in the prior year's quarter, indicating a positive trend in profitability. The company also announced its intention to separate its Biosciences and Diagnostic Solutions businesses, aiming to enhance shareholder value. This strategic move, expected to be completed in fiscal year 2026, suggests a focus on optimizing its portfolio and unlocking potential value. While the company navigates various legal and regulatory matters, including ongoing product liability claims and FDA inquiries, its financial performance shows resilience, supported by strong operational execution and strategic acquisitions.

Becton, Dickinson and Company (BDX) has filed an 8-K detailing two significant events. Firstly, the company announced its financial results for the first fiscal quarter ending December 31, 2024, via a press release furnished as Exhibit 99.1. This release includes both GAAP and non-GAAP financial measures, with further details on adjustments available within the release itself. Investors should refer to Exhibit 99.1 for a comprehensive understanding of BDX's recent performance. More strategically, BDX announced a significant move to separate its Biosciences and Diagnostic Solutions businesses. The board of directors has authorized management to pursue a plan for this separation, with more specifics expected by the end of fiscal 2025 and a target completion in fiscal 2026. While this move signals a potential restructuring, the company cautions that completion is contingent on various conditions, including board and regulatory approvals, and there's no guarantee of the transaction's form, terms, timing, or even its occurrence.

Becton Dickinson & Co. (BDX) has filed an 8-K reporting the results of its 2025 Annual Meeting of Shareholders held on January 28, 2025. The key outcomes include the overwhelming re-election of all director nominees, demonstrating continued shareholder confidence in the current board's leadership and strategy. Additionally, shareholders overwhelmingly ratified the appointment of Ernst & Young as the company's independent registered public accounting firm for fiscal year 2025, a crucial step for financial oversight and reporting integrity. Furthermore, the compensation of BDX's named executive officers was approved on an advisory, non-binding basis. While the majority voted in favor, the level of opposition and abstentions warrants attention from management to understand any underlying shareholder concerns regarding executive pay. Overall, the meeting signifies stable governance and a positive outlook on the company's financial auditing and executive compensation policies, with a minor area for management to address.

Becton, Dickinson and Company (BDX) has announced a key leadership change within its accounting department, appointing Pamela L. Spikner as Senior Vice President, Chief Accounting Officer and Controller, effective January 20, 2025. This appointment marks a significant addition to the company's financial leadership team, bringing in an executive with substantial experience from other publicly traded companies. Ms. Spikner's background includes serving as Chief Accounting Officer at R1 RCM and holding various accounting leadership roles at Exelon Corporation and Hill-Rom Holdings, Inc. Christopher DelOrefice, the current Executive Vice President and Chief Financial Officer, will continue to serve as interim principal accounting officer until the filing of the company's Form 10-Q for the quarter ended December 31, 2024. Following this transition, Ms. Spikner will assume the responsibilities of the principal accounting officer. The company has confirmed no specific arrangements or understandings influenced Ms. Spikner's appointment, nor any family relationships or related-person transactions, indicating a standard appointment process.

Becton, Dickinson and Company (BDX) reported revenues of $20.178 billion for the fiscal year ended September 29, 2024, representing a 4.2% increase year-over-year. This growth was driven by strong performance across its Medical, Life Sciences, and Interventional segments, notably boosted by the recent acquisition of Edwards Lifesciences' Critical Care product group. The company highlighted strategic objectives centered on growth, simplification, and empowerment, with a focus on innovation in smart devices, robotics, and AI. While facing some headwinds from market dynamics in China and inflationary pressures on labor and materials, BD demonstrated resilience with robust operating income and significant cash flow from continuing operations. The company continued to return value to shareholders through dividends and share repurchases. BD is actively managing various risks, including supply chain disruptions, regulatory scrutiny (particularly with its Alaris infusion pump business and a recent FDA warning letter for dispensing products), and cybersecurity threats. The company's proactive approach to risk management and commitment to innovation position it for continued development in the global medical technology market.

Becton, Dickinson and Company (BDX) filed an 8-K on November 7, 2024, to report its financial results for the fourth fiscal quarter ending September 30, 2024. The primary purpose of this filing is to provide investors with access to the company's earnings press release, which details the quarterly performance. Investors should refer to the press release (Exhibit 99.1) for comprehensive financial data and management commentary. The press release contains both GAAP and non-GAAP financial measures. BD explicitly notes that these non-GAAP measures differ from standard U.S. Generally Accepted Accounting Principles. Investors are advised to carefully review the schedules within the press release for reconciliations and explanations of these non-GAAP adjustments to ensure a complete understanding of the company's financial performance.

Becton, Dickinson and Company (BDX) announced on October 2, 2024, that it has reached an agreement to resolve the vast majority of its existing hernia litigation. This settlement covers cases in both Rhode Island and federal multidistrict litigation in Ohio. Importantly, the aggregate amount payable under this settlement is within BD's current product litigation reserve and will not result in an incremental charge to the company's consolidated income statement. The settlement payments will be made over a multi-year period, a plan that was already factored into BD's cash flow projections and capital allocation strategy. BD emphasizes that the settlement does not involve any admission of liability or wrongdoing, and the company continues to dispute the allegations. BD intends to vigorously defend itself in any cases not covered by this agreement. Investors should note that while this settlement aims to bring closure to a significant portion of the litigation, BD will continue to defend against any outstanding or future claims not included in this resolution. The company's forward-looking statements regarding the settlement are subject to various uncertainties, including plaintiff participation levels and potential future litigation.

Becton Dickinson & Co. (BDX) has announced a key executive leadership change, effective August 30th, 2024. Thomas Spoerel will transition from his role as Principal Accounting Officer to Senior Vice President, CFO Regions. In this new capacity, Spoerel will lead the financial integration of the recently announced acquisition of Edwards Lifesciences' Critical Care product group. This move signals a strategic focus on integrating the new business and leveraging regional finance leadership. Following Spoerel's departure from the Principal Accounting Officer role, Christopher DelOrefice, Executive Vice President and Chief Financial Officer, will assume these responsibilities on an interim basis. This appointment is designed to ensure continuity in financial reporting and oversight during this transition period. Investors should monitor the progress of the Edwards Life Sciences acquisition integration and its impact on BDX's financial performance.

Becton Dickinson and Company (BDX) reported solid revenue growth in the third quarter of fiscal year 2024, with total revenues reaching $4.99 billion, a 2.3% increase year-over-year. This growth was driven by strong performance in the Medical and Interventional segments, particularly in Medication Delivery Solutions and Urology and Critical Care, respectively. Net income for the quarter was $487 million, resulting in diluted earnings per share of $1.68, an improvement from $1.36 in the prior year's quarter. The company continues to strengthen its financial position, demonstrated by a significant increase in cash and equivalents and the successful issuance of new debt to fund strategic initiatives. A significant development during the quarter was the announcement of the definitive agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This strategic acquisition is expected to enhance BD's smart connected care solutions and is anticipated to close by the end of calendar year 2024, subject to regulatory approvals. The company also provided updates on ongoing legal matters, including product liability claims and regulatory investigations, noting a $50 million charge related to an SEC investigation into Alaris infusion pumps. Overall, BDX demonstrated resilience and strategic foresight, balancing operational execution with significant growth opportunities.

Becton, Dickinson and Company (BDX) filed an 8-K on August 1, 2024, primarily to furnish its press release announcing financial results for the third fiscal quarter ending June 30, 2024. The key takeaway for investors is the disclosure of the company's performance in the recently concluded quarter. The filing directs readers to Exhibit 99.1, the accompanying press release, for the detailed financial results and operational updates. Investors should pay close attention to the information presented in the press release, as it will contain the actual financial figures for revenue, earnings, and any segment-specific performance. The company also notes the use of non-GAAP financial measures, which are common in earnings releases and are provided alongside GAAP figures. Investors will need to review the press release to understand the specific non-GAAP adjustments and their impact on the reported results.

Becton, Dickinson and Company (BDX) announced on July 11, 2024, that it has successfully extended its senior unsecured revolving credit facility by one year. The facility, originally set to expire in September 2026, will now mature in September 2027. This extension, agreed upon by lenders on July 9, 2024, maintains the existing $2.75 billion credit line, which can be increased by an additional $500 million under certain conditions. This extension provides BDX with continued financial flexibility for general corporate purposes and reinforces its access to liquidity. The credit facility remains a crucial component of the company's financial strategy, with covenants tied to its Leverage Ratio and customary events of default. The ability to extend further for an additional year is also noted, subject to lender consent.

Becton, Dickinson and Company (BDX) has announced significant financing activities through multiple debt offerings, including €1 billion in 3.828% Notes due 2032, €800 million in 4.029% Notes due 2036 issued by its subsidiary Becton Dickinson Euro Finance S.à r.l. (guaranteed by BDX), and $600 million in 5.081% Notes due 2029. The primary purpose of these offerings is to fund the cash consideration for the anticipated acquisition of Edwards Lifesciences Corporation's Critical Care business, along with associated fees, expenses, and general corporate purposes. While these offerings are not contingent on the acquisition's completion, their proceeds are earmarked for this strategic move.

Becton, Dickinson and Company (BD) has announced a significant strategic move, entering into a definitive agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash. This acquisition is poised to bolster BD's presence in advanced monitoring solutions, a key area within critical care. This transaction represents a substantial investment and signals BD's commitment to expanding its portfolio in high-growth segments of the medical technology market. Investors should monitor the closing of this deal, as it is subject to regulatory approvals and integration challenges. The company has provided a press release and a presentation offering further details on the strategic rationale and financial implications of this acquisition.

Becton Dickinson & Co. (BDX) reported solid revenue growth for the third quarter of fiscal year 2024, with total revenues increasing by 4.6% year-over-year to $5.045 billion. This growth was driven by broad-based strength across its segments, particularly the Interventional segment, which saw a 9.0% increase in revenue, and the Medical segment's 3.8% rise. Net income applicable to common shareholders rose to $537 million from $438 million in the prior year, and diluted Earnings Per Share (EPS) improved to $1.85 from $1.53. The company's financial condition remains robust, with operating cash flows of $1.369 billion for the first six months of fiscal 2024. BDX also continued to return capital to shareholders through dividends, distributing $550 million. Despite some headwinds such as increased raw material and labor costs, and specific market dynamics in China, the company demonstrated effective cost management, with selling, general, and administrative expenses decreasing as a percentage of revenue. The company's outlook remains focused on its BD 2025 strategy centered on growth, simplification, and empowerment.

Becton, Dickinson and Company (BDX) filed an 8-K on May 2, 2024, to report its financial results for the second fiscal quarter ending March 31, 2024. The primary purpose of this filing is to furnish the press release announcing these results, which is included as Exhibit 99.1. Investors should note that the press release contains non-GAAP financial measures, and details regarding these adjustments are available within the press release itself.

Becton, Dickinson and Company (BDX) has filed an 8-K to announce the upcoming retirement of David Hickey, Executive Vice President and President of the Life Sciences segment, effective July 1, 2024. This departure is a significant leadership change within a key segment of the company. BD has stated its intention to appoint a successor before Mr. Hickey's retirement date, aiming for a smooth transition. This announcement, made via a press release filed on February 27, 2024, is primarily informational. Investors should monitor future communications for details regarding Mr. Hickey's successor and any potential strategic implications for the Life Sciences segment. While no immediate financial impact is detailed, leadership changes can sometimes precede shifts in strategy or operational focus.

Becton, Dickinson and Company (BD) announced on February 8, 2024, the issuance of significant debt offerings, comprising €750 million in 3.519% Notes due 2031 and $1.175 billion in U.S. dollar-denominated notes ($625 million in 4.874% Notes due 2029 and $550 million in 5.110% Notes due 2034). These offerings are primarily intended to refinance existing debt obligations, specifically maturing 2024 notes with higher interest rates. The company has outlined terms for redemption, including provisions for early redemption at the company's option under certain conditions (e.g., change in tax laws) and at a premium in the event of a change of control. The issuance of these new notes suggests a proactive approach by BD to manage its debt structure and interest expenses. Investors should note the specific interest rates and maturity dates, as well as the refinancing strategy which aims to replace near-term debt with longer-term obligations at potentially more favorable rates.